Meeting
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.
Authors
Carissa Beaulieu
Department of Medical Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada
Carissa Beaulieu , Sunita Ghosh , Camilla Tajzler , McKayla Kirkpatrick , Vincent Castonguay , Lori Wood , Jeffrey Graham , Denis Soulieres , Rahul K. Bansal , Daniel Yick Chin Heng , Antonio Finelli , Simon Tanguay , Aly-Khan A. Lalani , Bimal Bhindi , Georg A. Bjarnason , Rodney H. Breau , Naveen S. Basappa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 382)
DOI
10.1200/JCO.2024.42.4_suppl.382
Abstract #
382
Poster Bd #
F6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
First Author: Daniel M. Geynisman
Poster
2021 Genitourinary Cancers Symposium
Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.
First Author: Elizabeth R. Plimack
Poster
2024 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).
First Author: Viktor Grünwald
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world survival outcomes of patients (pts) treated with 6-weekly pembrolizumab 400mg (pem6w) plus axitinib (axi) for advanced renal cell carcinoma (aRCC).
First Author: Sonam Ansel